<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2207245621
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RAZON 40 MG E.C TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PANTOPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        35.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1055]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Dallah Health Care Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><br />RAZON contains the active substance pantoprazole. RAZON is a selective &ldquo;proton pump inhibitor&rdquo;, a medicine which reduces the<br />amount of acid produced in your stomach. It is used for treating acid-related diseases of the stomach and intestine.<br />RAZON 20 mg is used for:<br />Adults and adolescents 12 years of age and above for:<br />□ Symptoms (e.g. heartburn, acid regurgitation, pain on swallowing) associated to gastro-oesophageal reflux disease caused by reflux<br />of acid from the stomach.<br />□ Long-term management of reflux oesophagitis (inflammation of the oesophagus accompanied by the regurgitation of stomach acid)<br />and preventing its return.<br />Adults:<br />□ Preventing duodenal and stomach ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs, for example, ibuprofen) in<br />patients at risk who need to take NSAIDs continuously.<br />RAZON 40 mg is used for:<br />Adults and adolescents 12 years of age and above for:<br />□ Reflux oesophagitis. An inflammation of your oesophagus (the tube which connects your throat to your stomach) accompanied by<br />the regurgitation of stomach acid.<br />Adults:<br />□ An infection with a bacterium called Helicobacter pylori in patients with duodenal ulcers and stomach ulcers in combination with two<br />antibiotics (eradication therapy). The aim is to get rid of the bacteria and so reduce the likelihood of these ulcers returning.<br />□ Stomach and duodenal ulcers.<br />□ Zollinger-Ellison-Syndrome and other conditions producing too much acid in the stomach</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take RAZON:<br />□ If you are allergic to pantoprazole or to any of the other ingredients of this medicine (listed in section 6).<br />□ If you are allergic to medicines containing other proton pump inhibitors.<br />Take special care with RAZON:<br />Talk to your doctor, pharmacist or nurse before taking RAZON:<br />□ If you have severe liver problems. Please tell your doctor if you have ever had problems with your liver. He will check your liver<br />enzymes more frequently, especially when you are taking RAZON as a long-term treatment. In the case of a rise of liver enzymes the<br />treatment should be stopped.<br />□ If you need to take medicines called NSAIDs continuously and receive RAZON because you have an increased risk of developing<br />stomach and intestinal complications. Any increased risk will be assessed according to your own personal risk factors such as your<br />age (65 years old or more), a history of stomach or duodenal ulcers or of stomach or intestinal bleeding.<br />□ If you have reduced body stores or risk factors for reduced vitamin B12 and receive long-term treatment with pantoprazole. As with<br />all acid reducing agents, pantoprazole may lead to a reduced absorption of vitamin B12.<br />□ If you are taking HIV protease inhibitors such as atazanavir (for the treatment of HIV-infection) at the same time as pantoprazole,<br />ask your doctor for specific advice.<br />□Taking a proton pump inhibitor like pantoprazole, especially over a period of more than one year, may slightly increase your risk of<br />fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the<br />risk of osteoporosis).<br />□ If you are on RAZON for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of<br />magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. If<br />you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium<br />or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.<br />□ If you have ever had a skin reaction after treatment with a medicine similar to RAZON that reduces stomach acid.<br />□ If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop<br />your treatment with RAZON. Remember to also mention any other ill-effects like pain in your joints.<br />□ If you are due to have a specific blood tests (Chromogranin A).<br />Tell your doctor immediately, before or after taking RAZON, if you notice any of the following symptoms, which could be a sign of<br />another, more serious, disease:<br />□ An unintentional loss of weight<br />□ Vomiting, particularly if repeated<br />□ Vomiting blood; this may appear as dark coffee grounds in your vomit<br />□ You notice blood in your stools; which may be black or tarry in appearance<br />□ Difficulty in swallowing or pain when swallowing<br />□ You look pale and feel weak (anaemia)<br />□ Chest pain<br />□ Stomach pain<br />□ Severe and/or persistent diarrhoea, because RAZON has been associated with a small increase in infectious diarrhoea.<br />Your doctor may decide that you need some tests to rule out malignant disease because pantoprazole also alleviates the symptoms of<br />cancer and could cause delay in diagnosing it. If your symptoms continue in spite of your treatment, further investigations will be<br />considered.<br />If you take RAZON on a long-term basis (longer than 1 year) your doctor will probably keep you under regular surveillance. You<br />should report any new and exceptional symptoms and circumstances whenever you see your doctor.<br />Children and adolescents<br />RAZON is not recommended for use in children as it has not been proven to work in children below 12 years of age.<br />Taking RAZON with other medicines:<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained<br />without a prescription.<br />This is because RAZON may influence the effectiveness of other medicines, so tell your doctor if you are taking:<br />□ Medicines such as ketoconazole, itraconazole and posaconazole (used to treat fungal infections) or erlotinib (used for certain types<br />of cancer) because RAZON may stop these and other medicines from working properly.<br />□ Warfarin and phenprocoumon, which affect the thickening, or thinning of the blood. You may need further checks.<br />□ Medicines used to treat HIV-infection, such as atazanavir.<br />□ Methotrexate (used to treat rheumatoid arthritis, psoriasis, and cancer) &ndash; if you are taking methotrexate your doctor may temporarily<br />stop your RAZON treatment because pantoprazole can increase levels of methotrexate in the blood.<br />□ Fluvoxamine (used to treat depression and other psychiatric diseases &ndash; if you are taking fluvoxamine your doctor may reduce the<br />dose.<br />□ Rifampicin (used to treat infections).<br />□ St John&rsquo;s wort (Hypericum perforatum) (used to treat mild depression).<br />Pregnancy and breast-feeding<br />There are no adequate data from the use of pantoprazole in pregnant women. Excretion into human milk has been reported.<br />If you are pregnant or breast feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for<br />advice before taking this medicine.<br />You should use this medicine, only if your doctor considers the benefit for you greater than the potential risk for your unborn child or<br />baby.<br />Driving and using machines<br />RAZON has no or negligible influence on the ability to drive and use machines.<br />If you experience side effects like dizziness or disturbed vision, you should not drive or operate machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take RAZON exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br />Method of administration:<br />Take the tablets 1 hour before a meal without chewing or breaking them and swallow them whole with some water.<br />RAZON 20 mg:<br />The recommended dose is:<br />Adults and adolescents 12 years of age and above<br />□ To treat symptoms (e.g. heartburn, acid regurgitation, pain on swallowing) associated to gastro-oesophageal reflux disease<br />The usual dose is one tablet a day. This dose usually brings relief within 2 - 4 weeks &ndash; at most after another 4 weeks. Your doctor will<br />tell you how long to continue taking the medicine. After this, any recurring symptoms can be controlled by taking one tablet daily, when<br />required.<br />□ For long-term management and for preventing the return of reflux oesophagitis<br />The usual dose is one tablet a day. If the illness returns, your doctor can double the dose, in which case you can use RAZON 40 mg<br />tablets instead, one a day. After healing, you can reduce the dose back again to one tablet 20 mg a day.<br />Adults<br />To prevent duodenal and stomach ulcers in patients who need to take NSAIDs continuously<br />The usual dose is one tablet a day.<br />RAZON 40 mg:<br />The recommended dose is:<br />Adults and adolescents 12 years of age and above<br />□ To treat reflux oesophagitis<br />The usual dose is one tablet a day. Your doctor may tell you to increase to 2 tablets daily. The treatment period for reflux oesophagitis<br />is usually between 4 and 8 weeks. Your doctor will tell you how long to take your medicine.<br />Adults<br />□ For the treatment of an infection with a bacterium called Helicobacter pylori in patients with duodenal ulcers and stomach ulcers in<br />combination with two antibiotics (Eradication therapy).<br />One tablet, two times a day plus two antibiotic tablets of either amoxicillin, clarithromycin and metronidazole (or tinidazole), each to be<br />taken two times a day with your RAZON tablet. Take the first pantoprazole tablet 1 hour before breakfast and the second RAZON<br />tablet 1 hour before your evening meal. Follow your doctor&rsquo;s instructions and make sure you read the package leaflets for these<br />antibiotics. The usual treatment period is one to two weeks.<br />□ For the treatment of stomach and duodenal ulcers.<br />The usual dose is one tablet a day. After consultation with your doctor, the dose may be doubled.<br />Your doctor will tell you how long to take your medicine. The treatment period for stomach ulcers is usually between 4 and 8 weeks.<br />The treatment period for duodenal ulcers is usually between 2 and 4 weeks.<br />□ For the long-term treatment of Zollinger-Ellison-Syndrome and of other conditions in which too much stomach acid is produced.<br />The recommended starting dose is usually two tablets a day.<br />Take the two tablets 1 hour before a meal. Your doctor may later adjust the dose, depending on the amount of stomach acid you<br />produce. If prescribed more than two tablets a day, the tablets should be taken twice daily.<br />If your doctor prescribes a daily dose of more than four tablets a day, you will be told exactly when to stop taking the medicine.<br />Patients with kidney problems<br />If you have kidney problems, you should not take RAZON for eradication of Helicobacter pylori.<br />Patients with liver problems<br />□ If you suffer from severe liver problems, you should not take more than one tablet 20 mg pantoprazole a day.<br />□ If you suffer from moderate or severe liver problems, you should not take RAZON for eradication of Helicobacter pylori.<br />Use in children and adolescents<br />These tablets are not recommended for use in children below 12 years.<br />If you take more RAZON than you should<br />Consult your doctor or pharmacist. There are no known symptoms of overdose.<br />If you forget to take RAZON<br />Do not take a double dose to make up for a forgotten dose. Take your next normal dose at the usual time.If you stop taking RAZON<br />Do not stop taking these tablets without first talking to your doctor or pharmacist.<br />If you have any further questions about the use of this medicine, ask your doctor, pharmacist or nurse</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If you get any of the following side effects, stop taking these tablets and tell your doctor immediately, or contact the casualty<br />department at your nearest hospital:<br />Serious allergic reactions (frequency rare: may affect up to 1 in 1,000 people):<br />Swelling of the tongue and/or throat, difficulty in swallowing, hives (nettle rash), difficulties in breathing, allergic facial swelling<br />(Quincke&rsquo;s oedema / angioedema), severe dizziness with very fast heartbeat and heavy sweating.<br />Serious skin conditions (frequency not known: frequency cannot be estimated from the available data):<br />Blistering of the skin and rapid deterioration of your general condition, erosion (including slight bleeding) of eyes, nose, mouth/lips or<br />genitals (Stevens-Johnson-Syndrome, Lyell-Syndrome, Erythema multiforme), and sensitivity to light.<br />Other serious conditions (frequency not known: frequency cannot be estimated from the available data):<br />Yellowing of the skin or whites of the eyes (severe damage to liver cells, jaundice) or fever, rash, and enlarged kidneys sometimes<br />with painful urination, and lower back pain (serious inflammation of the kidneys), possibly leading to kidney failure.<br />Other side effects are:<br />Common (may affect up to 1 in 10 people)<br />Benign polyps in the stomach.<br />Uncommon (may affect up to 1 in 100 people)<br />Headache, dizziness, diarrhoea, feeling sick, vomiting, bloating and flatulence (wind), constipation, dry mouth, abdominal pain and<br />discomfort, skin rash, exanthema, eruption, itching; feeling weak, exhausted or generally unwell, sleep disorders, fracture in the hip,<br />wrist or spine.<br />Rare (may affect up to 1 in 1,000 people)<br />Distortion or complete lack of the sense of taste, disturbances in vision such as blurred vision, hives, pain in the joints, muscle pains,<br />weight changes, raised body temperature, high fever, swelling of the extremities (peripheral oedema), allergic reactions, depression,<br />breast enlargement in males.<br />Very Rare (may affect up to 1 in 10,000 people)<br />Disorientation.<br />Not known (frequency cannot be estimated from the available data)<br />Hallucination, confusion (especially in patients with a history of these symptoms); decreased sodium level in blood, decreased<br />magnesium level in blood (see section 2), feeling of tingling, prickling, pins and needles, burning sensation or numbness, rash,<br />possibly with pain in the joints.<br />Side effects identified through blood tests:<br />□ Uncommon (may affect up to 1 in 100 people): an increase in liver enzymes.<br />□ Rare (may affect up to 1 in 1,000 people) an increase in bilirubin; increased fat levels in blood; sharp drop in circulating granular<br />white blood cells associated with high fever.<br />□ Very Rare (may affect up to 1 in 10,000 people) a reduction in the number of blood platelets, which may cause you to bleed or<br />bruise more than normal; a reduction in the number of white blood cells, which may lead to more frequent infections; coexisting<br />abnormal reduction in the number of red and white blood cells, as well as platelets</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />□ Do not store above 30&deg;C, protected from humidity.<br />□ Do not use RAZON after the expiry date which is stated on the carton and on the blister, after (EXP).Date<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer<br />required. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What RAZON contains:<br />□ The active substance is Pantoprazole. Each Enteric Coated Tablet contains 20 and 40 mg of Pantoprazole, respectively, as<br />Pantoprazole Sodium.<br />□ The other ingredients are: Sodium Carbonate Decahydrate, Mannitol, Crospovidone, Povidone (K90), Calcium Stearate,<br />Hydroxypropyl Methyl Cellulose 2910, Povidone (K25), Titanium Dioxide, Iron Oxide Yellow, Propylene Glycol, Methacrylic acid<br />copolymer, Triethyl Citrate, Sodium Hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
□ RAZON 20 Tablets are beige circular shallow biconvex enteric coated tablets printed with “PZ2” on one side.
□ RAZON 40 Tablets are beige oval biconvex enteric coated tablets printed with “PZ4” on one side.
□ Boxes of 20 Blistered tablets of RAZON 20 Tablets.
□ Boxes of 30 Blistered tablets of RAZON 20 Tablets.
□ Boxes of 14 Blistered tablets of RAZON 40 Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Jordanian pharmaceutical manufacturing co.(P.L.C.|)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي رازون على المادة الفعالة بانتوبرازول. رازون هو مثبط اختياري لمضخة البروتون، وهو عبارة عن دواء يعمل على خفض إنتاج كمية الحمض في المعدة. يستخدم<br />في معالجة الأمراض المتعلقة في حمض المعدة والأمعاء.<br />يستخدم رازون ۲۰ ملغم ل:<br />البالغين والمراهقين الذين أعمارهم ۱۲ سنة فما فوق:<br />معالجة الأعراض (مثل، الحرقة، ارتجاع الحمض، الألم عند البلع) المرتبطة بمرض الارتداد المعدي المريئي والناجمة عن ارتجاع الحمض من المعدة. □<br />معالجة طويلة الأمد لالتهاب المريء الارتدادي (التهاب المريء المصحوب بارتجاع الحمض من المعدة) ومنع عودته. □<br />البالغين:<br />منع حدوث قرحة الاثني عشر والمعدة التي تسببها الأدوية المضادة للالتهاب غير الستيرويدية (مثل، أيبوبروفين) في المرضى المعرضين للخطر والذين يحتاجون □<br />لتناول الأدوية المضادة للالتهاب غير الستيرويدية باستمرار.<br />يستخدم رازون ٤۰ ملغم ل:<br />البالغين والمراهقين الذين أعمارهم ۱۲ سنة فما فوق:<br />التهاب المريء الارتدادي، وهو التهاب المريء (الأنبوب الذي يربط الحلق بالمعدة) المصحوب بارتجاع الحمض من المعدة. □<br />البالغين:<br />عدوى البكتيريا التي تسمى الملوية البوابية في المرضى الذين يعانون من قرحة الاثني عشر والمعدة بالاقتران مع اثنين من المضادات الحيوية (علاج استئصالي). □<br />والهدف من ذلك هو التخلص من البكتيريا وتقليل احتمال عودة هذه القرحات.<br />قرحة المعدة والاثني عشر. □<br />متلازمة زولينجر إليسون والحالات الأخرى التي تؤدي إلى إنتاج كميات كبيرة من الحمض في المعدة. □</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع استعمال رازون:<br />.( إذا كنت تعاني من حساسية لبانتوبرازول أو لأي من مكونات رازون الأخرى (انظر إلى القسم ٦ □<br />إذا كنت تعاني من حساسية لأدوية أخرى مثبطة لمضخة البروتون. □<br />الاحتياطات عند استعمال رازون:<br />تحدث مع طبيبك أو الصيدلي أو الممرضة قبل أخذ رازون:<br />إذا كنت تعاني من مشاكل وخيمة في الكبد. يرجى إخبار طبيبك إذا كنت تعاني في أي وقت مضى من مشاكل في الكبد، سيتحقق طبيبك من أنزيمات الكبد لديك بشكل □<br />أكثر تكراراً، وخصوصاً عند تناول رازون كعلاج طويل الأمد. يجب وقف المعالجة في حالة ارتفاع أنزيمات الكبد.<br />إذا كنت بحاجة لتناول الأدوية المضادة للالتهاب غير الستيرويدية بشكل مستمر وتتناول رازون لأنك عرضة بشكل متزايد لحدوث مضاعفات في المعدة والأمعاء. سيتم □<br />تقييم أي خطر متزايد وفقاً لعوامل الخطر الشخصية الخاصة بك مثل عمرك ( ٦٥ سنة أو أكثر) أو المعاناة مسبقاً من قرحة في الاثني عشر أو المعدة أو المعاناة من نزيف<br />معوي.<br />إذا كنت تعاني من انخفاض مخازن فيتامين ب ۱۲ في جسمك أو تعاني من عوامل الخطرالمرتبطة بانخفاض ب ۱۲ وتتلقى المعالجة باستخدام رازون على الأمد □<br />. الطويل. كما هو الحال مع جميع العوامل التي تؤدي إلى تقليل الحمض فإن رازون يؤدي إلى تقليل امتصاص فيتامين ب ۱۲<br />إذا كنت تتناول أدوية تحتوي على أتازانافير (يستخدم لمعالجة عدوى نقص المناعة البشرية) في نفس الوقت الذي تتناول فيه رازون فإن عليك استشارة طبيبك. □<br />أخذ مثبط لمضخة البروتون مثل بانتوبرازول، وخاصة على مدى فترة تزيد عن سنة واحدة، قد يزيد قليلاً من خطر حدوث كسر في الورك والمعصم أو العمود الفقري. □<br />أخبر طبيبك إذا كنت تعاني من هشاشة العظام أو إذا كنت تأخذ الستيروئيدات القشرية (التي يمكن أن تزيد من خطر هشاشة العظام).<br />إذا كنت تتناول رازون لأكثر من ثلاثة أشهر فمن الممكن أن مستويات المغنيسيوم في الدم قد تقل. و تظهر المستويات المنخفضة من المغنيسيوم على شكل تعب، □<br />تقلصات العضلات اللاارادية، ارتباك، تشنجات، دوخة و زيادة معدل ضربات القلب. إذا حصلت معك اي من هذه الأعراض ، يرجى إخبار الطبيب على الفور. انخفاض<br />مستويات المغنيسيوم يمكن أن يؤدي أيضا إلى انخفاض في مستويات البوتاسيوم أو الكالسيوم في الدم. قد يقرر طبيبك إجراء فحوصات دم منتظمة لمراقبة مستويات<br />المغنيسيوم لديك.<br />إذا عانيت في ما مضى من تفاعل جلدي بعد العلاج بدواء مشابه لرازون يقلل من حمض المعدة. □<br />إذا عانيت من طفح على جلدك، خاصة في المناطق المعرضة لأشعة الشمس أخبر طبيبك بأسرع ما يمكن. كما قد تحتاج إلى إيقاف علاجك برازون. تذكر أن تذكر أيضاً □<br />أي آثار سيئة أخرى مثل الألم في المفاصل.<br />(A إذا كان من المقرر أن تجري اختبارات دم محددة (كروموغرانين □<br />أخبر طبيبك مباشرة، قبل أو بعد أخذ رازون، إذا لاحظت أياً من الأعراض التالية و التي يمكن أن تكون علامة لمرض آخر أكثر خطورة:<br />خسارة الوزن غير المقصودة □<br />القيء خاصة إذا تكرر □<br />قيء الدم، قد يظهر هذا كقهوة داكنة في القيء □<br />لاحظت دم في البراز الخاص بك. والذي قد يكون أسود أو قطراني المظهر □<br />صعوبة في البلع أو الألم عند البلع □<br />الشحوب والشعور بالضعف (فقر الدم) □<br />ألم بالصدر □<br />آلام في المعدة □<br />إسهال وخيم و/أو مستمر، لأن رازون يرتبط بزيادة طفيفة بحدوث إسهال معد. □<br />قد يقرر طبيبك إن كنت بحاجة لعمل فحوصات لاستبعاد المرض الخبيث، لأن رازون يخفف أيضاً من أعراض السرطان وقد يؤدي إلى تأخير تشخيص هذا المرض.<br />إذا استمرت الأعراض لديك بالرغم من المعالجة فسوف يتم إجراء المزيد من التحقيقات.<br />إذا كنت تتناول رازون على المدى الطويل (أكثر من سنة)، فربما يبقيك طبيبك تحت المراقبة المنتظمة. يجب الإبلاغ عن أي أعراض أو حالات جديدة واستثنائية عند<br />مراجعة طبيبك.المراهقين<br />لا ينصح باستخدام رازون في الأطفال حيث أنه لم يثبت فعاليته في الاطفال دون سن ۱۲ سنة.<br />تناول رازون مع أدوية أخرى<br />يرجى إخبار الطبيب أو الصيدلاني إذا كنت تأخذ أو أخذت مؤخراً أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.<br />وذلك لأن رازون قد يؤثر على فعالية الأدوية الأخرى، لذلك أخبر طبيبك إذا كنت تأخذ:<br />الأدوية مثل كيتوكونازول و إيتراكونازول و بوساكونازول (يستخدم لمعالجة العدوى الفطرية) أو إيرلوتينب (يستخدم لمعالجة أنواع معينة من السرطان) لأن رازون □<br />قد يعمل على إيقاف آلية العمل الصحيحة لهذه الأدوية وغيرها.<br />وارفارين و فينوبروكومون، التي تؤثر على ثخانة أو ترقق الدم. قد تحتاج إلى مزيد من التحقق. □<br />الأدوية التي تستخدم لمعالجة عدوى نقص المناعة البشرية مثل أتازانافير □<br />ميثوتريكسيت (دواء يستخدم لعلاج التهاب المفاصل الروماتويدي، والصدفية، وبعض أنواع السرطان)، إذا كنت تأخذ الميثوتريكسيت فقد يوقف طبيبك العلاج باستخدام □<br />رازون مؤقتاً بسبب زيادة مستوى الميثوتريكسيت في الدم نتيجة استخدام رازون .<br />فلوفوكسامين (يستخدم لعلاج الاكتئاب وغيرها من الأمراض النفسية - إذا كنت تأخذ فلوفوكسامين قد الطبيب يقلل الجرعة. □<br />ريفامبيسين (يستخدم لعلاج الالتهابات). □<br />نبتة سانت جون (هيبيريكوم بيرفوراتوم) (المستخدمة لعلاج الاكتئاب الخفيف). □<br />الحمل والرضاعة:<br />لا توجد معلومات كافية حول استخدام رازون لدى النساء الحوامل. تم الإبلاغ عن إفرازه في حليب الأم.<br />إذا كنت حاملاُ أو مرضعة، أو تعتقدي بأنك حامل أو تخططين للإنجاب ، اسألي طبيبك أو الصيدلاني للحصول على المشورة قبل تناول هذا الدواء.<br />يجب عليك استخدام هذا الدواء، فقط إذا كان طبيبك يعتبر الفائدة بالنسبة لك أكبر من المخاطر المحتملة لطفلك أو الطفل الذي لم يولد بعد.<br />تأثير المستحضر على القيادة واستخدام الآلات:<br />لا يوجد لرازون أي تأثير يذكر على القدرة على قيادة واستخدام الآلات.<br />لا يجب أن تقود السيارة أو تشغل الآلات إذا واجهت آثاراً جانبية مثل الدوخة أو اضطرابات في الرؤية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أخبرك طبيبك. يجب أن تسأل طبيبك أو الصيدلاني إذا كنت غير متأكد.<br />طريقة الإعطاء:<br />خذ الأقراص قبل ساعة واحدة من الطعام دون مضغها أو كسرها و ابتلعهم مع بعض الماء.<br />رازون ۲۰ ملغم:<br />الجرعة التي ينصح بها:<br />للبالغين والمراهقين الذين أعمارهم ۱۲ سنة فما فوق:<br />معالجة الأعراض (مثل، الحرقة، ارتجاع الحمض، الألم عند البلع) المرتبطة بمرض الارتجاع المعدي المريئي: □<br />٤ أسابيع، وكحد أقصى بعد ٤ أسابيع أخرى. سيخبرك - الجرعة الاعتيادية هي قرص واحد من رازون ۲۰ ملغم يومياً. تؤدي هذه الجرعة إلى إزالة الأعراض خلال ۲<br />طبيبك عن المدة اللازمة لمواصلة تناولك للدواء. يمكن السيطرة على أي أعراض متكررة بعد ذلك عن طريق تناول قرص واحد من رازون ۲۰ ملغم يومياً عند<br />الحاجة.<br />معالجة طويلة الأمد لالتهاب المريء الجزري ومنع عودته: □<br />الجرعة الاعتيادية هي قرص واحد من رازون ۲۰ ملغم يومياً. في حال عودة المرض يمكن لطبيبك مضاعفة الجرعة، وفي هذه الحالة يمكنك استخدام قرص رازون ٤۰<br />ملغم بدلاً من ذلك مرة واحدة يومياً. بعد الشفاء، يمكنك تقليل الجرعة مرة أخرى إلى قرص واحد من رازون ۲۰ ملغم يومياً.<br />للبالغين:<br />منع حدوث قرحة الاثني عشر والمعدة في المرضى الذين يحتاجون لتناول الأدوية المضادة للالتهاب غير الستيرويدية بشكل مستمر، الجرعة الاعتيادية هي قرص واحد<br />من رازون ۲۰ ملغم يومياً.<br />رازون ٤۰ ملغم:<br />الجرعة التي ينصح بها:<br />للبالغين والمراهقين الذين أعمارهم ۱۲ سنة فما فوق:<br />معالجة التهاب المريء الجزري: □<br />الجرعة الاعتيادية هي قرص واحد من رازون ٤۰ ملغم يومياً. قد يطلب منك طبيبك بأن ترفع الجرعة إلى قرصين في اليوم. عادةً ما تتراوح فترة المعالجة لالتهاب<br />المريء الجزري ما بين ٤ و ۸ أسابيع. سيخبرك طبيبك عن المدة اللازمة لتناول الدواء.<br />للبالغين:<br />معالجة عدوى البكتيريا التي تسمى الملوية البوابية في المرضى الذين يعانون من قرحة الاثني عشر والمعدة بالاقتران مع نوعين من المضادات الحيوية □<br />(علاج استئصالي):<br />قرص واحد، مرتين في اليوم بالإضافة إلى قرصين من المضادات الحيوية سواء أموكسيسيلين، كلاريثرومايسين و ميترونيدازول (أو تينيدازول) التي يجب اتخاذها مرتين<br />في اليوم مع أقراص رازون.<br />تناول أول قرص من رازون قبل ساعة من وجبة الفطور والقرص الثاني قبل ساعة من وجبة المساء. اتبع تعليمات طبيبك، وتأكد من قراءة النشرات لهذه المضادات<br />الحيوية. تتراوح فترة المعالجة المعتادة من أسبوع واحد إلى أسبوعين.<br />معالجة قرحة المعدة والاثني عشر: □<br />الجرعة الاعتيادية هي قرص واحد من رازون ٤۰ ملغم يومياً. يمكن مضاعفة الجرعة بعد استشارة طبيبك. سيخبرك طبيبك عن المدة اللازمة لتناول الدواء. تتراوح فترة<br />المعالجة المعتادة لقرحة المعدة ما بين ٤ و ۸ أسابيع. تتراوح فترة المعالجة المعتادة لقرحة الاثني عشر ما بين ۲ و ٤ أسابيع.<br />معالجة طويلة الأمد لمتلازمة زولينجر إليسون والحالات الأخرى التي تؤدي إلى إنتاج كميات كبيرة من الحمض في المعدة: □<br />جرعة البدء الموصى بها تكون بالعادة قرصين في اليوم. تناول القرصين قبل ساعة من الوجبة. قد يعدل طبيبك الجرعة في وقت لاحق اعتماداًعلى كمية الحمض التي<br />تنتجها المعدة.إذا وصف لك أكثر من قرصين في اليوم ، يجب أخذ الأقراص مقسمة على مرتين في اليوم.<br />إذا وصف لك الطبيب جرعة يومية تصل إلى أكثر من أربعة أقراص في اليوم، فإنه سيتم إخبارك عن الوقت المحدد لوقف تناول الدواء.<br />المرضى الذين يعانون من مشاكل في الكلى<br />إذا كنت تعاني من مشاكل في الكلى فإنه لا يجب تناول رازون لاستئصال الملوية البوابية.<br />المرضى الذين يعانون من مشاكل في الكبد<br />إذا كنت تعاني من مشاكل وخيمة في الكبد فإنه لا يجب تناول أكثر من قرص واحد ۲۰ ملغم بانتوبرازول في اليوم. □<br />إذا كنت تعاني من مشاكل معتدلة إلى وخيمة في الكبد فإنه لا يجب تناول رازون لاستئصال الملوية البوابية. □<br />الاستخدام في الأطفال و المراهقين<br />لا ينصح باستخدام هذه الأقراص للأطفال دون سن الثاني عشر.<br />الجرعة الزائدة من رازون:<br />إذا تناولت أقراص رازون أكثر مما يجب فإنه يجب عليك إخبار طبيبك أو الصيدلاني. لا توجد أعراض معروفة للجرعة الزائدة.<br />إذا نسيت تناول رازون:<br />RZ/19/230/ لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. تناول جرعتك التالية في وقتها المعتاد.لتوقف عن تناول رازون:<br />لا تتوقف عن تناول هذه الأقراص دون استشارة طبيبك أو الصيدلاني أولاً.<br />استشر طبيبك أو الصيدلاني أو الممرض إذا كان لديك أي أسئلة اخرى حول استعمال هذا المستحضر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كغيره من الأدوية، قد يسبب رازون أعراضاً جانبيةً، بالرغم من أنها لاتحدث للجميع.<br />توقف عن تناول هذه الأقراص و أخبر طبيبك مباشرةً أو اتصل بقسم الطوارئ في أقرب مستشفى، إذا حدثت معك أياً من الأعراض الجانبية التالية:<br />تفاعلات حساسية خطيرة (نادرة الحدوث: قد تؤثر على شخص واحد من ۱۰۰۰ شخص):<br />تورم اللسان و/أو الحلق، صعوبة في البلع، شرى (طفح القراص)، صعوبة في التنفس، حساسية و تورم الوجه (وذمة وعائية)، دوخة شديدة مع نبضات قلب سريعة وتعرق<br />غزير.<br />تفاعلات جلدية خطيرة (تكرار حدوثها غير معروف: لا يمكن تقدير تكرار حدوثها من البيانات المتاحة ):<br />تقرحات في الجلد وتدهور شديد في الحالة العامة، تآكل (يشمل نزيف طفيف) في العيون أو الأنف أو الفم/الشفاه أو الأعضاء التناسلية (متلازمة ستيفينز جونسون، ملازمة<br />لايل، حمامى عديدة الأشكال) والحساسية للضوء.<br />حالات شديدة أخرى (تكرار حدوثها غير معروف: لا يمكن تقدير تكرار حدوثها من البيانات المتاحة):<br />اصفرار الجلد أو بياض العينين (أضرار شديدة في خلايا الكبد، يرقان) أو حمى، طفح و تضخم الكلى في بعض الأحيان مع ألم في التبول وآلام في أسفل الظهر (التهاب<br />خطير في الكلى)، مما قد يؤدي إلى الفشل الكلوي.<br />الأعراض الجانبية الأخرى:<br />أعراض جانبية شائعة (قد تؤثر على شخص من ۱۰ شخص):<br />الأورام الحميدة في المعدة.<br />أعراض جانبية غير شائعة (قد تؤثر على شخص من ۱۰۰ شخص):<br />صداع، دوخة، إسهال، غثيان، قيء، تطبل و انتفاخ (ريح)، إمساك، جفاف الفم، ألم في البطن و الشعور بعدم الراحة، طفح جلدي، طفح ظاهر، طفح، حكة، الشعور<br />بالضعف، التوعك، اضطرابات في النوم.<br />أعراض جانبية نادرة (قد تؤثر على شخص من ۱۰۰۰ شخص):<br />تحور أو فقدان كامل لحاسة التذوق، اضطرابات في الرؤية مثل تغيم الرؤية، شرى، آلام في المفاصل، آلام في العضلات، تغيرات في الوزن، ارتفاع حرارة الجسم، حمى<br />شديدة، تورم الأطراف (وذمة طرفية)، تفاعلات الحساسية، اكتئاب، تضخم الثدي عند الذكور.<br />أعراض جانبية نادرة جداً (قد تؤثر على شخص من ۱۰۰۰۰ شخص):<br />توهان.<br />أعراض جانبية غير معروفة (لا يمكن تقدير تكرار حدوثها من البيانات المتوفرة):<br />هلوسة، ارتباك (خصوصاً المرضى الذين لديهم تاريخ لهذه الأعراض)، انخفاض مستوى الصوديوم في الدم ، انخفاض مستوى المغنيزيوم في الدم (انظر قسم ۲)، الشعور<br />بالوخز، النخز كدبابيس وإبر، إحساس بالحرقان أو تنميل، طفح جلدي، ربما ألم في المفاصل.<br />الأعراض الجانبية التي تم تحديدها خلال فحوصات الدم:<br />أعراض جانبية غير شائعة (قد تؤثر على شخص من ۱۰۰ شخص): زيادة في إنزيمات الكبد. □<br />أعراض جانبية نادرة (قد تؤثر على شخص من ۱۰۰۰ شخص): زيادة البيليروبين، زيادة مستويات الدهون في الدم، انخفاض حاد في خلايا الدم البيضاء المحببة □<br />المرتبطة بارتفاع درجة الحرارة.<br />أعراض جانبية نادرة جداً (قد تؤثر على شخص من ۱۰۰۰۰ شخص): انخفاض في عدد الصفائح الدموية مما قد يسبب لك نزيف أو كدمات أكثر من المعتاد، انخفاض □<br />في عدد خلايا الدم البيضاء مما قد يؤدي إلى المزيد من حالات العدوى المتكررة، انخفاض غير طبيعي في عدد خلايا الدم الحمراء و البيضاء و كذلك الصفائح الدموية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن متناول الأطفال □<br />لا يحفظ بدرجة حرارة أعلى من ۳۰ &deg;م، يحفظ بعيداً عن الرطوبة. □<br />لا ينبغي استعمال رازون بعد تاريخ انتهاء الصلاحية الموجود على العلبة وعلى شريط الدواء. □<br />لا ينبغي التخلص من الأدوية من خلال مياه الصرف الصحي أو المنزلي. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه الاجراءات<br />على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما هي محتويات رازون:<br />المادة الفعالة هي بانتوبرازول. كل قرص مغلف معوي يحتوي على ۲۰ ملغم و ٤۰ ملغم من بانتوبرازول على التوالي، على هيئة بانتوبرازول صوديوم. □<br />ستيارات الكالسيوم، هيدروكسي بروبيل ميثيل سلولوز، بوفيدون ، (K المكونات الأخرى هي: كربونات الصوديوم ديكاهيدرات، مانيتول، كروسبوفيدون، بوفيدون ( ۹۰ □<br />ثنائي أكسيد التيتانيوم، أكسيد الحديد الأصفر، بروبيلين جلايكول، حمض الميثاكريليك بلمر مشترك، ثلاثي إيثيل السترات، هيدروكسيد الصوديوم. ، (K۲٥)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>من جانب واحد . &ldquo;PZ أقراص رازون ۲۰ هي أقراص مغلفة معوية لونها بيج، دائرية الشكل ثنائية التحدب مسطحة مطبوع عليها &rdquo; 2 □ من جانب واحد . &ldquo;PZ أقراص رازون ٤۰ هي أقراص مغلفة معوية لونها بيج ، بيضوية الشكل ثنائية التحدب مطبوع عليها &rdquo; 4 □ علب تحتوي على ۲۰ قرص من رازون ۲۰ محفوظة في أشرطة. □ علب تحتوي على ۳۰ قرص من رازون ۲۰ محفوظة في أشرطة. □ علب تحتوي على ۱٤ قرص من رازون ٤۰ محفوظة في أشرطة. □</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة الاردنية لانتاج الادوية المساهمة العامة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             آذار ۲۰۱۸
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RAZON 40 mg Enteric Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient:
 Pantoprazole 40 mg (as Pantoprazole Sodium).

Inactive ingredients:

Ingredient	Quantity
mg/tab.
Sodium Carbonate. Decahydrate 	10.0
Mannitol	46.0
Crospovidone (polyplasdone XL)	52.7
Povidone (K90)	4.0
Calcium Stearate	3.3
Hydroxypropyl Methyl Cellulose 2910  (Methocel E3)	10.3
Povidone (K25)	0.2
Titanium Dioxide	0.2
Iron Oxide Yellow	0.02
Propylene Glycol	2.3
Methacrylic acid copolymer (Type L 100-55)	13.5
Triethyl Citrate 	1.3
Sodium Hydroxide	0.2

      *For a full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Beige oval biconvex enteric coated tablets printed with “PZ4” on one side of tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RAZON is indicated for use in adults and adolescents 12 years of age and above for:</p><p>&sect;&nbsp; Reflux oesophagitis.</p><p>&nbsp;</p><p>RAZON is indicated in adults for:</p><p>&sect;&nbsp; Eradication of <em>Helicobacter pylori</em> (<em>H. pylori</em>) in combination with appropriate antibiotic therapy in patients with <em>H. pylori</em> associated ulcers.</p><p>&sect;&nbsp; Gastric and duodenal ulcer.</p><table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>&sect;&nbsp; Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions.</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Method of administration</u></p><p>Oral use</p><p>The tablets should not be chewed or crushed, and should be swallowed whole 1 hour before a meal with some water.</p><p><strong>4-2-1&nbsp;&nbsp;&nbsp;&nbsp; Recommended dose:</strong></p><p><strong>&nbsp;</strong></p><p><em>Adults and adolescents 12 years of age and above:</em></p><p><em>&nbsp;</em></p><p><u>Reflux oesophagitis</u></p><p><u>&nbsp;</u></p><p>One tablet of Pantoprazole 40 mg per day. In individual cases the dose may be doubled (increase to 2 tablets of Pantoprazole 40 mg daily) especially when there has been no response to other treatment. A 4-week period is usually required for the treatment of reflux oesophagitis. If this is not sufficient, healing will usually be achieved within a further 4 weeks.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Adults:</em></p><p><em>&nbsp;</em></p><p><u>Eradication of <em>H. pylori</em> in combination with two appropriate antibiotics</u></p><p><u>&nbsp;</u></p><p>In <em>H. pylori</em> positive patients with gastric and duodenal ulcers, eradication of the germ by a combination therapy should be achieved. Considerations should be given to official local guidance (e.g. national recommendations) regarding bacterial resistance and the appropriate use and prescription of antibacterial agents. Depending upon the resistance pattern, the following combinations can be recommended for the eradication of <em>H. pylori</em>:</p><p>&nbsp;</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; twice daily one tablet of RAZON</p><p>+ twice daily 1000 mg amoxicillin</p><p>+ twice daily 500 mg clarithromycin</p><p>&nbsp;</p><p>b) twice daily one tablet of RAZON</p><p>+ twice daily 400 - 500 mg metronidazole (or 500 mg tinidazole)</p><p>+ twice daily 250 - 500 mg clarithromycin</p><p>&nbsp;</p><p>c) twice daily one tablet of RAZON</p><p>+ twice daily 1000 mg amoxicillin</p><p>+ twice daily 400 - 500 mg metronidazole (or 500 mg tinidazole).</p><p>&nbsp;</p><p>In combination therapy for eradication of H. pylori infection, the second Pantoprazole tablet should be taken 1 hour before the evening meal. The combination therapy is implemented for 7 days in general and can be prolonged for a further 7 days to a total duration of up to two weeks. If, to ensure healing of the ulcers, further treatment with Pantoprazole is indicated, the dosage recommendations for duodenal and gastric ulcers should be considered.</p><p>&nbsp;</p><p>If combination therapy is not an option, e.g. if the patient has tested negative for <em>H. pylori</em>, the following dosage guidelines apply for Pantoprazole monotherapy:</p><p>&nbsp;</p><p><u>Treatment of gastric ulcer</u></p><p><u>&nbsp;</u></p><p>One tablet of Pantoprazole 40 mg per day. In individual cases the dose may be doubled (increase to 2 tablets of Pantoprazole 40 mg daily) especially when there has been no response to other treatment. A 4-week period is usually required for the treatment of gastric ulcers. If this is not sufficient, healing will usually be achieved within a further 4 weeks.</p><p>&nbsp;</p><p><u>Treatment of duodenal ulcer</u></p><p><u>&nbsp;</u></p><p>One tablet of Pantoprazole 40 mg per day. In individual cases the dose may be doubled (increase to 2 tablets of Pantoprazole 40 mg daily) especially when there has been no response to other treatment. A duodenal ulcer generally heals within 2 weeks. If a 2-week period of treatment is not sufficient, healing will be achieved in almost all cases within a further 2 weeks.</p><p>&nbsp;</p><p><u>Zollinger-Ellison syndrome and other pathological hypersecretory conditions</u></p><p><u>&nbsp;</u></p><p>For the long-term management of Zollinger-Ellison syndrome and other pathological hypersecretory conditions patients should start their treatment with a daily dose of 80 mg (2 tablets of RAZON 40 mg). Thereafter, the dosage can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dosage above 160 mg Pantoprazole is possible but should not be applied longer than required for adequate acid control.</p><p>Treatment duration in Zollinger-Ellison syndrome and other pathological hypersecretory conditions is not limited and should be adapted according to clinical needs.</p><p>&nbsp;</p><p><strong>4-2-2&nbsp;&nbsp;&nbsp;&nbsp; Special populations:</strong></p><p><strong>&nbsp;</strong></p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>Pantoprazole is not recommended for use in children below 12 years of age due to limited data on safety and efficacy in this age group.</p><p>&nbsp;</p><p><em>Patients with Hepatic impairment:</em></p><p><em>&nbsp;</em></p><p>A daily dose of 20 mg Pantoprazole (1 tablet of 20 mg pantoprazole) should not be exceeded in patients with severe liver impairment. RAZON must not be used in combination treatment for eradication of <em>H. pylori</em> in patients with moderate to severe hepatic dysfunction since currently no data are available on the efficacy and safety of Pantoprazole in combination treatment of these patients (see section 4.4).</p><p>&nbsp;</p><p><em>Patients with Renal impairment:</em></p><p><em>&nbsp;</em></p><p>No dose adjustment is necessary in patients with impaired renal function. RAZON must not be used in combination treatment for eradication of H. pylori in patients with impaired renal function since currently no data are available on the efficacy and safety of RAZON in combination treatment for these patients.</p><p>&nbsp;</p><p><em>Older people:</em></p><p><em>&nbsp;</em></p><p>No dose adjustment is necessary in older people</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, substituted benzimidazoles or to any of the other excipients
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Hepatic impairment</em></p><p><em>&nbsp;</em></p><p>In patients with severe liver impairment the liver enzymes should be monitored regularly during treatment with Pantoprazole, particularly on long-term use. In the case of a rise of the liver enzymes the treatment should be discontinued (see section 4.2).</p><p><em>&nbsp;</em></p><p><em>Combination therapy</em></p><p>&nbsp;</p><p>In the case of combination therapy, the summaries of product characteristics of the respective medicinal products should be observed.</p><p>&nbsp;</p><p><em>Gastric malignancy</em></p><p><em>&nbsp;</em></p><p>Symptomatic response to pantoprazole may mask the symptoms of gastric malignancy and may delay diagnosis. In the presence of any alarm symptom (e. g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis, anaemia or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded.</p><p>Further investigation is to be considered if symptoms persist despite adequate treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>Co-administration with HIV protease inhibitors</em></p><p><em>&nbsp;</em></p><p>Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, due to significant reduction in their bioavailability (see section 4.5).</p><p>&nbsp;</p><p><em>Influence on vitamin B12 absorption</em></p><p>&nbsp;</p><p>In patients with Zollinger-Ellison syndrome and other pathological hypersecretory conditions requiring long-term treatment, Pantoprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if respective clinical symptoms are observed.</p><p>&nbsp;</p><p><em>Long term treatment</em></p><p><em>&nbsp;</em></p><p>In long-term treatment, especially when exceeding a treatment period of 1 year, patients should be kept under regular surveillance.</p><p>&nbsp;</p><p><em>Gastro-intestinal infections caused by bacteria</em></p><p><em>&nbsp;</em></p><p>Treatment with RAZON may lead to a slightly increased risk of gastrointestinal infections caused by bacteria such as <em>Salmonella</em> and <em>Campylobacter</em> or <em>C. difficile</em>.</p><p>&nbsp;</p><p><em>Hypomagnesaemia</em></p><p><em>&nbsp;</em></p><p>Severe hypomagnesaemia has been reported in patients treated with PPIs like Pantoprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g. diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p>&nbsp;</p><p><em>Bone fractures</em></p><p><em>&nbsp;</em></p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors.</p><p>Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10&ndash;40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p>&nbsp;</p><p><em>Subacute cutaneous lupus erythematosus (SCLE)</em></p><p><em>&nbsp;</em></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the healthcare professional should consider stopping RAZON. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p>&nbsp;</p><p>Interference with Laboratory Tests</p><p>&nbsp;</p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, RAZON treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Medicinal products with pH-Dependent Absorption Pharmacokinetics</u></em></p><p><u>&nbsp;</u></p><p>Because of profound and long lasting inhibition of gastric acid secretion, Pantoprazole may reduce the absorption of drugs with a gastric pH dependent bioavailability, e.g some azole antifungals such as ketoconazole, itraconazole,</p><p>posaconazole and other medicines such as erlotinib.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>HIV protease inhibitors</u></em></p><p><em>&nbsp;</em></p><p>Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir due to significant reduction in their bioavailability(see section 4.4).</p><p>&nbsp;</p><p>If the combination of HIV protease inhibitors with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g virus load) is recommended. A pantoprazole dose of 20 mg per day should not be exceeded. Dosage of the HIV protease inhibitors may need to be adjusted.</p><p>&nbsp;</p><p><em><u>Coumarin anticoagulants (phenprocoumon or warfarin)</u></em></p><p><em>&nbsp;</em></p><p>Co-administration of pantoprazole with warfarin or phenprocoumon did not affect the pharmacokinetics of warfarin, phenprocoumon or INR. However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin or phenprocoumon concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding, and even death. Patients treated with pantoprazole and warfarin or phenprocoumon may need to be monitored for increase in INR and prothrombin time.</p><p>&nbsp;</p><p><em><u>Methotrexate</u></em></p><p><em><u>&nbsp;</u></em></p><p>Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients. Therefore in settings where high-dose methotrexate is used, for example cancer and psoriasis, a temporary withdrawal of pantoprazole may need to be considered.</p><p>&nbsp;</p><p><em><u>Other interactions studies</u></em></p><p><em>&nbsp;</em></p><p>Pantoprazole is extensively metabolized in the liver via the cytochrome P450 enzyme system. The main metabolic pathway is demethylation by CYP2C19 and other metabolic pathways include oxidation by CYP3A4.</p><p>&nbsp;</p><p>Interaction studies with drugs also metabolized with these pathways, like carbamazepine, diazepam, glibenclamide, nifedipine, and an oral contraceptive containing levonorgestrel and ethinyl oestradiol did not reveal clinically significant interactions.</p><p>&nbsp;</p><p>An interaction of pantoprazole with other medicinal products or compounds, which are metabolized using the same enzyme system, cannot be excluded.</p><p>&nbsp;</p><p>Results from a range of interaction studies demonstrate that Pantoprazole does not affect the metabolism of active substances metabolised by CYP1A2 (such as caffeine, theophylline), CYP2C9 (such as piroxicam, diclofenac, naproxen), CYP2D6 (such as metoprolol), CYP2E1 (such as ethanol) or does not interfere with p-glycoprotein related absorption of digoxin.</p><p>&nbsp;</p><p>There were no interactions with concomitantly administered antacids.</p><p>&nbsp;</p><p>Interaction studies have also been performed administering Pantoprazole concomitantly with the respective antibiotics (clarithromycin, metronidazole, amoxicillin) no clinically relevant interactions were found.</p><p>&nbsp;</p><p>Medicinal products that inhibit or induce CYP2C19:</p><p>&nbsp;</p><p>Inhibitors of CYP2C19 such as fluvoxamine could increase the systemic exposure of pantoprazole. A dose reduction may be considered for patients treated long-term with high doses of pantoprazole, or those with hepatic impairment.</p><p>&nbsp;</p><p>Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin and St John&acute;s wort (<em>Hypericum perforatum</em>) may reduce the plasma concentrations of PPIs that are metabolized through these enzyme systems</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1-1-1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use during pregnancy</p><p>A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformative or feto/ neonatal toxicity of RAZON.</p><p>Animal studies have shown reproductive toxicity (see section 5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of RAZON during pregnancy.</p><p>1-1-2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use during lactation</p><p>Animal studies have shown excretion of Pantoprazole in breast milk. Excretion into human milk has been reported.</p><p>Therefore a decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Pantoprazole should be made taking into account the benefit of breast-feeding to the child and the benefit of Pantoprazole therapy to the woman.</p><p>&nbsp;</p><p>1-1-3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fertility</p><p>There was no evidence of impaired fertility following the administration of pantoprazole in animal studies (see section 5.3).</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole has no or negligible influence on the ability to drive and use</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; machines.</p><p>Adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or operate machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Approximately 5 % of patients can be expected to experience adverse drug reactions (ADRs). The most commonly reported ADRs are diarrhoea and headache, both occurring in approximately 1 % of patients.</p><p>&nbsp;</p><p>The table below lists adverse reactions reported with pantoprazole, ranked under the following frequency classification:</p><p>&nbsp;</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>For all adverse reactions reported from post-marketing experience, it is not possible to apply any Adverse Reaction frequency and therefore they are mentioned with a &ldquo;not known&rdquo; frequency.</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Table 1. Adverse reactions with Pantoprazole in clinical trials and post-marketing experience.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Common</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Rare</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Very rare</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Agranulocytosis</p></td><td style="vertical-align:top"><p>Thrombocytopenia; Leukopenia; Pancytopenia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity (including anaphylactic reactions and anaphylactic shock)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyperlipidaemias and lipid increases (triglycerides, cholesterol); Weight changes</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyponatraemia; Hypomagnesaemia (see section 4.4); Hypocalcaemia <sup>(1)</sup>; Hypokalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Sleep disorders</p></td><td style="vertical-align:top"><p>Depression (and all aggravations)</p></td><td style="vertical-align:top"><p>Disorientation (and all aggravations)</p></td><td style="vertical-align:top"><p>Hallucination; Confusion (especially in pre-disposed patients, as well as the aggravation of these symptoms in case of pre-existence)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Headache; Dizziness</p></td><td style="vertical-align:top"><p>Taste disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Parasthesia</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Disturbances in vision / blurred vision</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Fundic gland polyps (benign)</p></td><td style="vertical-align:top"><p>Diarrhoea; Nausea / vomiting; Abdominal distension and bloating; Constipation; Dry mouth; Abdominal pain and discomfort</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Liver enzymes increased (transaminases, &gamma;-GT)</p></td><td style="vertical-align:top"><p>Bilirubin increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hepatocellular injury; Jaundice; Hepatocellular failure</p></td></tr><tr><td style="vertical-align:top"><p>Skin and sub-cutaneous tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash / exanthema / eruption; Pruritus</p></td><td style="vertical-align:top"><p>Urticaria; Angioedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Stevens-Johnson syndrome; Lyell syndrome; Erythema multiforme; Photosensitivity; Sub-acute cutaneous lupus erythematosus (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Fracture of the hip, wrist or spine (see section 4.4)</p></td><td style="vertical-align:top"><p>Arthralgia; Myalgia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Muscle spasm <sup>(2)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Interstitial nephritis (with possible progression to renal failure)</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Asthenia, fatigue and malaise</p></td><td style="vertical-align:top"><p>Body temperature increased; Oedema peripheral</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><sup>1. </sup>Hypocalcemia in association with hypomagnesemia</p><p><sup>2. </sup>Muscle spasm as a consequence of electrolyte disturbance</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect (s):</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia: National Pharmacovigilance &amp; Drug Safety Centre (NPC)</p><p>q&nbsp; Fax: +966-11-205-7662</p><p>q&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>q&nbsp; Toll free phone: 8002490000</p><p>q&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>q&nbsp; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known symptoms of overdose in man.</p><p>&nbsp;</p><p>Systemic exposure with up to 240 mg administered intravenously over 2 minutes were well tolerated. As Pantoprazole is extensively protein bound, it is not readily dialyzable.</p><p>&nbsp;</p><p>In the case of an overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1-1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</p><p>&nbsp;Pharmacotherapeutic group: Proton pump inhibitors</p><p>&nbsp;ATC Code: A02BC02</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific action on the proton pumps of the parietal cells.</p><p>&nbsp;</p><p>Pantoprazole is converted to its active form in the acidic environment of the parietal cells where it inhibits the H+, K+- ATPase enzyme, i. e. the final stage in the production of hydrochloric acid in the stomach. The inhibition is dosedependent and affects both basal and stimulated acid secretion. In most patients, freedom from symptoms is achieved within 2 weeks. As with other proton pump inhibitors and H2 receptor inhibitors, treatment with Pantoprazole</p><p>reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible. Since Pantoprazole binds to the enzyme distal to the cell receptor level, it can inhibit hydrochloric</p><p>acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin). The effect is the same whether the product is given orally or intravenously.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>The fasting gastrin values increase under Pantoprazole. On short-term use, in most cases they do not exceed the upper limit of normal. During long-term treatment, gastrin levels double in most cases. An excessive increase,</p><p>however, occurs only in isolated cases. As a result, a mild to moderate increase in the number of specific endocrine (ECL) cells in the stomach is observed in a minority of cases during long-term treatment (simple to adenomatoid</p><p>hyperplasia). However, according to the studies conducted so far, the formation of carcinoid precursors (atypical hyperplasia) or gastric carcinoids as were found in animal experiments (see section 5.3) have not been observed in humans.</p><p>&nbsp;</p><p>An influence of a long term treatment with Pantoprazole exceeding one year cannot be completely ruled out on endocrine parameters of the thyroid according to results in animal studies.</p><p>&nbsp;</p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours.</p><p>&nbsp;</p><p>Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>Pantoprazole is rapidly absorbed and the maximal plasma concentration is achieved even after one single 40 mg oral dose. On average at about 2.5 h p.a. the maximum serum concentrations of about 2 - 3 &micro;g/ml are achieved, and these values remain constant after multiple administration.</p><p>&nbsp;</p><p>Pharmacokinetics does not vary after single or repeated administration. In the dose range of 10 to 80 mg, the plasma kinetics of pantoprazole are linear after both oral and intravenous administration.</p><p><u>&nbsp;</u></p><p>The absolute bioavailability from the tablet was found to be about 77 %. Concomitant intake of food had no influence on AUC, maximum serum concentration and thus bioavailability. Only the variability of the lag-time will be increased by concomitant food intake.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>Pantoprazole&#39;s serum protein binding is about 98%. Volume of distribution is about 0.15 l/kg.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>The substance is almost exclusively metabolized in the liver. The main metabolic pathway is demethylation by CYP2C19 with subsequent sulphate conjugation; other metabolic pathway includes oxidation by CYP3A4.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>Terminal half-life is about 1 hour and clearance is about 0.1 l/h/kg. There were a few cases of subjects with delayed elimination. Because of the specific binding of pantoprazole to the proton pumps of the parietal cell the elimination half-life does not correlate with the much longer duration of action (inhibition of acid secretion).</p><p><u>&nbsp;</u></p><p>Renal elimination represents the major route of excretion (about 80 %) for the metabolites of Pantoprazole; the rest is excreted with the faeces. The main metabolite in both the serum and urine is desmethylpantoprazole which is</p><p>conjugated with sulphate. The half-life of the main metabolite (about 1.5 hours) is not much longer than that of Pantoprazole.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<u>Pharmacokinetic in specific patient groups</u></em></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Poor metabolisers</em></p><p>Approximately 3 % of the European population lack a functional CYP2C19 enzyme and are called poor metabolisers.</p><p>In these individuals the metabolism of Pantoprazole is probably mainly catalysed by CYP3A4. After a single-dose administration of 40 mg Pantoprazole, the mean area under the plasma concentration-time curve was approximately 6 times higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers).</p><p>Mean peak plasma concentrations were increased by about 60 %. These findings have no implications for the posology of Pantoprazole.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>&nbsp;</p><p>No dose reduction is requested when Pantoprazole is administered to patients with impaired kidney function (including dialysis patients). As with healthy subjects, Pantoprazole&#39;s half-life is short. Only very small amounts of Pantoprazole can be dialyzed. Although the main metabolite has a moderately delayed half-life (2 - 3h), excretion is still rapid and thus accumulation dose not occur.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>&nbsp;</p><p>Although for patients with liver cirrhosis (classes A and B according to Child) the half-life values increased to between 7 and 9 h and the AUC values increased by a factor of 5 - 7, the maximum serum concentration only increased</p><p>slightly by a factor of 1.5 compared with healthy subjects.</p><p>&nbsp;</p><p><em>Older people</em></p><p>&nbsp;</p><p>A slight increase in AUC and Cmax in elderly volunteers compared with younger counterparts is also not clinically relevant.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>&nbsp;</p><p>Following administration of single oral doses of 20 or 40 mg Pantoprazole to children aged 5 &ndash; 16 years AUC and C<sub>max</sub> were in the range of corresponding values in adults.</p><p>Following administration of single i.v. doses of 0.8 or 1.6 mg/kg Pantoprazole to children aged 2 &ndash; 16 years there was no significant association between Pantoprazole clearance and age or weight. AUC and volume of distribution were in accordance with data from adults.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard to humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.</p><p>&nbsp;</p><p>In the two-year carcinogenicity studies in rats neuroendocrine neoplasms were found. In addition, squamous cell papillomas were found in the forestomach of rats in one study. The mechanism leading to the formation of gastric carcinoids by substituted benzimidazoles has been carefully investigated and allows the conclusion that it is a secondary reaction to the massively elevated serum gastrin levels occurring in the rat during chronic high-dose treatment.</p><p>&nbsp;</p><p>In the two-year rodent studies an increased number of liver tumors was observed in rats (in one rat study only) and in female mice and was interpreted as being due to pantoprazole&#39;s high metabolic rate in the liver.</p><p>&nbsp;</p><p>A slight increase of neoplastic changes of the thyroid was observed in the group of rats receiving the highest dose (200 mg/kg). The occurrence of these neoplasms is associated with the Pantoprazole-induced changes in the breakdown of thyroxine in the rat liver. As the therapeutic dose in man is low, no side effects on the thyroid glands are expected.</p><p>&nbsp;</p><p>In animal reproduction studies, signs of slight fetotoxicity were observed at doses above 5 mg/kg.</p><p>&nbsp;</p><p>Investigations revealed no evidence of impaired fertility or teratogenic effects.</p><p>Penetration of the placenta was investigated in the rat and was found to increase with advanced gestation. As aresult, concentration of Pantoprazole in the foetus is increased shortly before birth.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:546px"><tbody><tr><td style="vertical-align:top"><p>&sect;&nbsp; Sodium Carbonate. Decahydrate</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Mannitol</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Crospovidone (polyplasdone XL)</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Povidone (K90)</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Calcium Stearate</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Hydroxypropyl Methyl Cellulose 2910&nbsp; (Methocel E3)</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Povidone (K25)</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Titanium Dioxide</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Iron Oxide Yellow</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Propylene Glycol</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Methacrylic acid copolymer (Type L 100-55)</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Triethyl Citrate</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C, protected from humidity</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RAZON 40 Enteric Coated Tablets are packed in boxes of 14 Tablets blistered in aluminium foil</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;Any unused product or waste material should be disposed of in</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Jordanian Pharmaceutical Manufacturing Co. Ltd.
PO Box 151
Um Al-Amad 16197
Jordan

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>